Cargando…
Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
Programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) blocking therapy has completely changed the treatment pattern of malignant tumors. It has been tested in a wide range of malignant tumors and achieved clinical success. It might be a promising cancer treatment strategy. However,...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492972/ https://www.ncbi.nlm.nih.gov/pubmed/34631560 http://dx.doi.org/10.3389/fonc.2021.731175 |